Therefore, our data indicate that the specific activation of CD271 within the context of a clinical protocol involving the use of platinum-based or 5-FU therapeutics [71, 72] could determine a higher sensitivity of cSCC cancer cells to differentiation and cell death, especially for the advanced conditions. This evidence concerns the gene NGFR and cancer.